## **Guest editorial:**

## DRUG-INDUCED MITOCHONDRIAL IMPAIRMENT IN LIVER CELLS

Regina Stöber

Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo), Ardeystrasse 67, 44139 Dortmund, Germany; e-mail: stoeber@ifado.de

http://dx.doi.org/10.17179/excli2015-764

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/).

Recently, Laia Tolosa and colleagues from Valencia University have published a study how to identify compounds that cause hepatotoxicity due to compromising mitochondrial functions (Tolosa et al., 2015). The authors used a set of fluorescent probes for imaging: HepG2 cells were loaded with Hoechst 33342 for cell number determination, cell viability was determined with propidium iodid and Mitotracker Green FM was applied for quantification of mitochondrial mass (Tolosa et al., 2015). For a more detailed analysis of compromised mitochondria, the authors used Fluo-4 AM to detect changes in cytoplasmic free calcium, Mitotracker Deep Red for analysis of mitochondrial localization, MitoSOX Red to analyze generation of superoxide by mitochondria, TMRM to study mitochondrial membrane potential and YO-PRO-1 for detection of apoptotic cells. Using this set of markers and quantitative imaging techniques the authors classified a set of well-known mitochondrial hepatotoxicants with excellent accuracy (Tolosa et al., 2015).

Drug or chemically induced liver injury represents a cutting-edge topic in toxicology (Benet et al., 2014; Campos et al., 2014; Vitins et al., 2014; Liu et al., 2014; Godoy and Bolt, 2012; Vinken et al., 2012; Liang et al., 2011; Hammad et al., 2011). Nu-

merous research projects aim at establishing in vitro systems to predict human hepatotoxicity (Chen et al., 2014; Grinberg et al., 2014; Carvalho et al., 2004; O'Brien et al., 2006; Reif, 2015; Shinde et al., 2015a, b; Kim et al., 2015; Pfeiffer et al., 2015). One of the limitations of current research is that it still remains challenging to predict doses that are associated with an increased risk of hepatotoxicity in vivo (Ghallab, 2013; Reif, 2014). Moreover, cultivated cells undergo major changes compared to hepatocytes in an intact liver (Godov et al., 2015, 2013, 2009; Zellmer et al., 2010; Hewitt et al., 2007; Hengstler et al., 2000). Despite of the still remaining challenges the high-content screening platform established by Tolosa and colleagues represents an important milestone.

## REFERENCES

Benet M, Moya M, Donato MT, Lahoz A, Hervás D, Guzmán C, et al. A simple transcriptomic signature able to predict drug-induced hepatic steatosis. Arch Toxicol. 2014;88:967-82.

Campos G, Schmidt-Heck W, Ghallab A, Rochlitz K, Pütter L, Medinas DB, et al. The transcription factor CHOP, a central component of the transcriptional regulatory network induced upon CCl4 intoxication in mouse liver, is not a critical mediator of hepatotoxicity. Arch Toxicol. 2014;88:1267-80.

Carvalho M, Milhazes N, Remião F, Borges F, Fernandes E, Amado F, et al. Hepatotoxicity of 3,4-methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Arch Toxicol. 2004;78:16-24.

Chen M, Tung CW, Shi Q, Guo L, Shi L, Fang H, et al. A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model. Arch Toxicol. 2014;88:1439-49.

Ghallab A. In vitro test systems and their limitations. EXCLI J. 2013;12:1024-6.

Godoy P, Bolt HM. Toxicogenomic-based approaches predicting liver toxicity in vitro. Arch Toxicol. 2012;86:1163-4.

Godoy P, Hengstler JG, Ilkavets I, Meyer C, Bachmann A, Müller A, et al. Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis. Hepatology. 2009;49:2031-43.

Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol. 2013;87:1315-530.

Godoy P, Schmidt-Heck W, Natarajan K, Lucendo-Villarin B, Szkolnicka D, Asplund A, et al. Gene networks and transcription factor motifs defining the differentiation of stem cells into hepatocyte-like cells. J Hepatol. 2015;63:934-42.

Grinberg M, Stöber RM, Edlund K, Rempel E, Godoy P, Reif R, et al. Toxicogenomics directory of chemically exposed human hepatocytes. Arch Toxicol. 2014;88:2261-87.

Hammad MA, Abdel-Bakky MS, Walker LA, Ashfaq MK. Oxidized low-density lipoprotein and tissue factor are involved in monocrotaline/lipopolysaccharide-induced hepatotoxicity. Arch Toxicol. 2011;85:1079-89.

Hengstler JG, Utesch D, Steinberg P, Platt KL, Diener B, Ringel M, et al. Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab Rev. 2000;32:81-118.

Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev. 2007;39: 159-234.

Kim JY, Fluri DA, Marchan R, Boonen K, Mohanty S, Singh P, et al. 3D spherical microtissues and microfluidic technology for multi-tissue experiments and analysis. J Biotechnol. 2015;205:24-35.

Liang QN, Sheng YC, Jiang P, Ji LL, Xia YY, Min Y, et al. The difference of glutathione antioxidant system in newly weaned and young mice liver and its involvement in isoline-induced hepatotoxicity. Arch Toxicol. 2011;85:1267-79.

Liu A, Krausz KW, Fang ZZ, Brocker C, Qu A, Gonzalez FJ. Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity. Arch Toxicol. 2014;88:983-96.

O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter M, ret al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol. 2006;80:580-604.

Pfeiffer E, Kegel V, Zeilinger K, Hengstler JG, Nüssler AK, Seehofer D, et al. Featured article: Isolation, characterization, and cultivation of human hepatocytes and non-parenchymal liver cells. Exp Biol Med (Maywood). 2015;240:645-56.

Reif R. The body-on-a-chip concept: possibilities and limitations. EXCLI J. 2014;13:1283-5.

Reif R. Highlight report: Mitochondrial depolarization by ethanol. Arch Toxicol. 2015;89:2195-6.

Shinde V, Klima S, Sureshkumar PS, Meganathan K, Jagtap S, Rempel E, et al. Human pluripotent stem cell based developmental toxicity assays for chemical safety screening and systems biology data generation. J Vis Exp. 2015a;17(100):e52333.

Shinde V, Stöber R, Nemade H, Sotiriadou I, Hescheler J, Hengstler J, et al. Transcriptomics of hepatocytes treated with toxicants for investigating molecular mechanisms underlying hepatotoxicity. Methods Mol Biol. 2015b;1250:225-40.

Tolosa L, Carmona A, Castell JV, Gómez-Lechón MJ, Donato MT. High-content screening of druginduced mitochondrial impairment in hepatic cells: effects of statins. Arch Toxicol. 2015;89:1847-60.

Vinken M, Pauwels M, Ates G, Vivier M, Vanhaecke T, Rogiers V. Screening of repeated dose toxicity data present in SCC(NF)P/SCCS safety evaluations of cosmetic ingredients. Arch Toxicol. 2012;86:405-12.

Vitins AP, Kienhuis AS, Speksnijder EN, Roodbergen M, Luijten M, van der Ven LT. Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models. Arch Toxicol. 2014;88: 1573-88.

Zellmer S, Schmidt-Heck W, Godoy P, Weng H, Meyer C, Lehmann T, et al. Transcription factors ETF, E2F, and SP-1 are involved in cytokine-independent proliferation of murine hepatocytes. Hepatology. 2010;52:2127-36.